Dermatology, Licensing and Medicine - Clinical Research Informer

Lebrikizumab Could Soon Be a New Treatment for Atopic Dermatitis

XTalks

APRIL 17, 2023

These results are very promising for patients with atopic dermatitis,” said Jonathan Silverberg, MD, professor of dermatology at George Washington University School of Medicine & Health Sciences and co-investigator of the studies, in the company’s press release.

Dermatology

Dermatology Antibody Clinical Trials Clinical Trials

First biologic approved in Scotland for hidradenitis suppurativa since 2016

Drug Discovery World

FEBRUARY 16, 2024

Novartis’ Cosentyx (secukinumab) is now available in Scotland, following positive advice from the Scottish Medicines Consortium (SMC). It is licensed for adults with active moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic HS therapy.

Dermatology

Dermatology Licensing Licensing Medicine

Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata

The Pharma Data

OCTOBER 29, 2020

Data support baricitinib’s ongoing Phase 3 program and potential to be the first approved medicine for people living with alopecia areata (AA). . The data underscore Lilly’s commitment to providing medicines for dermatologic diseases that have high unmet need, including alopecia areata (AA). INDIANAPOLIS , Oct.

Dermatology

Dermatology Development Medicine Clinical Trials

J&J presents successful data from plaque psoriasis trial

Drug Discovery World

MARCH 13, 2024

“Data from the FRONTIER 2 study showed that the skin clearance as seen by PASI 75 and higher-bar PASI 90 and 100 responses at 16 weeks was maintained at 52 weeks with no new safety signals across all JNJ-2113 treatment groups,” said Dr Laura Ferris, Professor of Dermatology, University of Pittsburgh.

Trials

Trials Dermatology Clinical Trials Clinical Trials

Almirall demonstrates resilient performance year to date despite COVID-19 impacts

The Pharma Data

NOVEMBER 8, 2020

Almirall strengthens its leadership in medical dermatology by reinforcing its management team in France and obtaining reimbursement in France of Ilumetri ® (tildrakizumab) for treating moderate to severe chronic plaque psoriasis in adults. Dermatology shows resilience in Europe and initial signs of recovery in the US.

Dermatology

Dermatology Sales Marketing Production

Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly’s Pivotal Phase 3 Studies

The Pharma Data

MARCH 27, 2022

Food and Drug Administration (FDA) granted priority review for OLUMIANT in severe AA as a potential first-in-disease medicine. associate professor of dermatology at Yale School of Medicine and lead author of these analyses. OLUMIANT, a once-daily, oral JAK inhibitor was discovered by Incyte and licensed to Lilly.

Dermatology

Dermatology Medicine Licensing Licensing

Dermavant raises $200m to ease launch of Otezla rival tapinarof

pharmaphorum

JUNE 8, 2021

It’s the second unusual royalty-focused deal to be entered into by a biotech in the last few days, after MorphoSys signed over future revenues from out-licensed medicines to fund its $1.7 billion takeover of Constellation Pharma.

Sales

Sales Dermatology Licensing Licensing

Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units

The Pharma Data

AUGUST 17, 2021

These changes will increase Lilly’s focus on introducing breakthrough new medicines to millions of people with unmet needs. Effective September 5, Lilly Bio-Medicines will split into two business units: Lilly Neuroscience and Lilly Immunology. Ricks, Lilly’s chairman and CEO. except for Canada.

Medicine

Medicine Dermatology Production Development

Lilly’s lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials

The Pharma Data

AUGUST 16, 2021

Fast Track designation is granted for a medicine that is intended to treat a serious condition and data demonstrate the potential to address an unmet medical need. associate professor of dermatology at George Washington University School of Medicine and Health Sciences in Washington, DC, and a principal investigator of the ADvocate 2 trial.

Dermatology

Dermatology Trials Bioavailability Medicine

Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly’s Lebrikizumab Atopic Dermatitis Monotherapy Trials

The Pharma Data

JUNE 7, 2022

“We look forward to providing an important new medicine and helping patients find the relief they so desperately seek from the varied and debilitating symptoms of this disease, contingent upon FDA approval.” With these data, Lilly plans to submit a Biologics License Application (BLA) to the U.S. Almirall S.A.’s

Trials

Trials Clinical Trials Clinical Trials Medicine

Update on US regulatory review of Fasenra in chronic rhinosinusitis with nasal polyps

The Pharma Data

MARCH 15, 2022

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for Fasenra (benralizumab) for patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). Fasenra was developed by AstraZeneca and is in-licensed from BioWa, Inc.,

Trials

Trials Medicine Licensing Licensing

FDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™ (adalimumab-afzb) Interchangeability

The Pharma Data

FEBRUARY 25, 2022

Food and Drug Administration (FDA) has accepted for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA™ (adalimumab-afzb) as an interchangeable biosimilar to Humira® (adalimumab). Pfizer Inc. NYSE: PFE) today announced that the U.S.

FDA Approval

FDA Approval Production Medicine Dermatology

Tezepelumab regulatory submission accepted and granted FDA Priority Review in the US for the treatment of patients with asthma

The Pharma Data

JULY 8, 2021

AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for the treatment of asthma from the US Food and Drug Administration (FDA). Despite recent advances in severe asthma, many patients may not qualify for or respond well to current biologic medicines.

Trials

Trials Medicine Sales Clinical Trials

CoolSculpting® by Allergan Aesthetics Expands Body Contouring Portfolio With CoolSculpting® Elite

The Pharma Data

FEBRUARY 5, 2021

American Society for Dermatologic Surgery (ASDS) consumer survey on cosmetic dermatologic procedures 2018 available at [link]. AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. N= 3,525 total study population.

Cosmetics

Cosmetics Dermatology Allergies Production

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. NEW YORK and LONDON, Jan. He has in depth Global Development Expertise (e.g.

Life Science

Life Science Antibody In-Vivo In-Vitro

Medical Aesthetics: “Redefining Beauty through Medical Expertise”

Roots Analysis

JANUARY 3, 2024

Medical aesthetics is a growing area of modern medicine that focuses on improving the cosmetic appearance of an individual through various medical treatments. Medical Aesthetics is an area of medicine that specializes in improving the cosmetic appearance of an individual through non invasive and minimally invasive procedures.

Filler

Filler Cosmetics Production Dermatology

Vitiligo Miracle Video – Heal Vitiligo In 7 Days

The Pharma Data

MAY 13, 2021

Featuring latest research from American Journal of Clinical Dermatology. Description: 1 Weird Trick To Easily Cure Vitiligo For Good In As Little As 7 Days – Guaranteed! Scientific References. For program support please. contact us here. For order support please. contact Clickbank here.

Production

Production Sales Dermatology Licensing

17 creams to STOP ITCHING FAST

Druggist

DECEMBER 9, 2020

Topical steroids are not directly classified as anti-itch medicines; however, it is thought that reduced skin itchiness comes from controlling skin inflammation (ibid). Pharmacy-only medicines can only be purchased from pharmacies, including online chemists. Clobetasone has a narrow licensed use. very potent steroid creams.

Pharmacy

Pharmacy Containment Sales Production

Lymecycline for ACNE: Questions & Answers

Druggist

MARCH 17, 2021

Both drugs are the same medicines. Although licensed for acne, minocycline is rarely prescribed in the UK. Strauss JS, Krowchuk DP, Leyden JJ, American Academy of Dermatology/American Academy of Dermatology Association, et al. How does lymecycline work for acne? Available at: [link] Accessed on 17/03/2021.

Bacteria

Bacteria Dermatology Doctors Doctor

Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed. | Novartis

The Pharma Data

APRIL 26, 2021

COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. Excluding prior year COVID-19 related forward purchasing , we estimate Q1 net sales grew +1% (cc, +4% USD), with Innovative Medicines growing +3% (cc, +7% USD)². Free cash flow¹ of USD 1.6

Sales

Sales Medicine Production Manufacturing

New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis

The Pharma Data

APRIL 6, 2021

. “We look forward to continuing to work closely with the FDA to bring baricitinib to patients living with moderate to severe atopic dermatitis,” said Ilya Yuffa, senior vice president and president of Lilly Bio-Medicines. About Lilly in Dermatology. See the full Prescribing Information here. BA HCP ISI 09JUL2020.

Drugs

Drugs Dermatology Clinical Trials Clinical Trials

Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus

The Pharma Data

AUGUST 1, 2021

Saphnelo is a first-in-class type I interferon receptor antibody and the only new medicine in over a decade for patients with systemic lupus erythematosus . This ground-breaking medicine has the potential to meaningfully improve the lives of patients living with this often debilitating disease.”. 12,13,14,15.

Trials

Trials Clinical Development Antibody Dermatology

Concert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company Update

The Pharma Data

NOVEMBER 4, 2020

Both of our clinical candidates represent important opportunities for new medicines that we hope will have a meaningful impact on the lives of patients.”. Published Findings on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology. License and research and development revenue.

Clinical Trials

Clinical Trials Clinical Trials Trials Dermatology

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

The Pharma Data

MARCH 4, 2021

associate professor of Dermatology at Yale School of Medicine. AA is the second potential treatment indication in dermatology for baricitinib after AD. ” Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly. It is approved and commercially available as OLUMIANT in the U.S.

Trials

Trials Development Dermatology Clinical Trials

Bayer: successful start to 2021

The Pharma Data

MAY 18, 2021

This included net special gains of 15 million euros (Q1 2020: net special charges of 639 million euros), with income from a patent dispute related to the blood-clotting medicine Jivi™ more than offsetting the expenses for the ongoing restructuring program. EBIT increased by 23.4 percent to 3.083 billion euros. Net income rose by 40.3

Sales

Sales Production Marketing Containment

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

The Pharma Data

SEPTEMBER 15, 2020

The results demonstrated that Penta immune responses were robust and noninferior to licensed meningococcal vaccines (MenB and MenACWY) in individuals 10-25 years of age, regardless of prior MenACWY exposure. Internal Medicine. Inflammation and Immunology. approval in 2021.

Gene Therapy

Gene Therapy Vaccination Vaccine Trials

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. In this in-depth article, we embark on a captivating journey to uncover the top 30 pharma and biotech companies that have been instrumental in shaping the future of medicine.

Sales

Sales Manufacturing FDA Approval Life Science

How GSK, Chiesi Farmaceutici, Regeneron/Sanofi, Novartis, and AB Science are trying to benefit patients afflicted with Inadequately Controlled Asthma?

Delveinsight

AUGUST 13, 2020

In February 2020, GSK announced the acceptance of regulatory submission seeking an additional indication for the use of Trelegy Ellipta for the treatment of asthma in adults by the European Medicines Agency (EMA). Conclusions : The addition of UMEC improved trough FEV, independently of baseline blood eosinophil and FeNO levels.

Antibody

Antibody Medicine Trials Development

Amgen Reports Second Quarter 2021 Financial Results

The Pharma Data

AUGUST 3, 2021

. “As we look to the balance of the year, we are excited to be launching LUMAKRAS , a first-in-class lung cancer treatment, and advancing a robust pipeline of potential new medicines to meet the demands of patients around the world.” 4% Dividends Paid Per Share $ 1.76 $ 1.60 Tezepelumab. Manufacturing Facilities.

Sales

Sales Production Antibody Development

Clinical Research Informer

Lebrikizumab Could Soon Be a New Treatment for Atopic Dermatitis

First biologic approved in Scotland for hidradenitis suppurativa since 2016

Trending Sources

Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata

J&J presents successful data from plaque psoriasis trial

Almirall demonstrates resilient performance year to date despite COVID-19 impacts

Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly’s Pivotal Phase 3 Studies

Dermavant raises $200m to ease launch of Otezla rival tapinarof

Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units

Lilly’s lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials

Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly’s Lebrikizumab Atopic Dermatitis Monotherapy Trials

Update on US regulatory review of Fasenra in chronic rhinosinusitis with nasal polyps

FDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™ (adalimumab-afzb) Interchangeability

Tezepelumab regulatory submission accepted and granted FDA Priority Review in the US for the treatment of patients with asthma

CoolSculpting® by Allergan Aesthetics Expands Body Contouring Portfolio With CoolSculpting® Elite

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

Medical Aesthetics: “Redefining Beauty through Medical Expertise”

Vitiligo Miracle Video – Heal Vitiligo In 7 Days

17 creams to STOP ITCHING FAST

Lymecycline for ACNE: Questions & Answers

Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed. | Novartis

New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis

Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus

Concert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company Update

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

Bayer: successful start to 2021

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

How GSK, Chiesi Farmaceutici, Regeneron/Sanofi, Novartis, and AB Science are trying to benefit patients afflicted with Inadequately Controlled Asthma?

Amgen Reports Second Quarter 2021 Financial Results

Stay Connected